Oncogenic osteomalacia and metastatic breast cancer: a case report and review of the literature

ConclusionsTo our knowledge, this is the first reported case of oncogenic osteomalacia in a patient with breast cancer. Oncogenic osteomalacia constitutes a diagnostic and therapeutic challenge. Pre-clinical and clinical evidence suggest that a possible underlying mechanism is the presence of molecular alterations in the FGF/FGFR signalling pathway leading to overexpression of FGF23. In metastatic setting, anticancer treatment can potentially lead to the normalisation of the electrolytic disturbances and reduction of the activity of oncogenic osteomalacia. The use of antiresorptive therapy in patients with bone metastases can potentially trigger FGF23 overexpression. Its use should be guided by the patients ’ risk of skeletal-related events and electrolytic disturbances as well as the degree of activity of oncogenic osteomalacia.
Source: Journal of Diabetes and Metabolic Disorders - Category: Endocrinology Source Type: research